Could a new combination therapy improve outcomes for patients with advanced melanoma?

Moffitt Cancer Center· @MoffittNews · X·2026-10-23 22:45· 2 days agoScore45

Body

At #ESMO26, Nikhil Khushalani, MD (@DrKhushalani), shares encouraging results from a global phase 3 trial evaluating HBI-8000 plus nivolumab, which could help establish a new standard of care. #MoffittESMO26

387 views · 4 likes · 3 reposts · 0 replies

Conference abstracts

2081PNCT04949113 NCT04949113 NCT04949113matched by Melanoma

Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity

https://esmocongress.esmo.org

4736Omatched by Proffered paper 1: Genitourinary tumour, renal and urothelial

Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)

https://esmocongress.esmo.org

4757ROmatched by Rapid oral 1: Genitourinary tumours, renal and urothelial

Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)

https://esmocongress.esmo.org

LBA54matched by Proffered paper: Melanoma and other skin tumours

Primary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma

https://esmocongress.esmo.org

NCT04884282NCT04884282matched by - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

Source: Moffitt Cancer Center · x.com